| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 2,420 | 2,680 | 23.06. |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 10.06. | Aclarion, Inc.: Aclarion to Present at the Planet MicroCap Las Vegas Powered by MicroCapClub | 2 | GlobeNewswire (USA) | ||
| 09.06. | Aclarion partners with PRIA Healthcare on market access program | 4 | Investing.com | ||
| 09.06. | Aclarion, Inc.: Aclarion Partners with PRIA Healthcare to Advance Reimbursement and Commercial Adoption of Its AI-Powered Nociscan Platform | 274 | GlobeNewswire (Europe) | Partnership supports reimbursement strategy and U.S. commercial expansion for Aclarion's AI-driven platform for chronic low back pain. Program aims to follow successful reimbursement wins in the UK... ► Artikel lesen | |
| 08.06. | Aclarion Comments on Echo Lake News | 1 | Baystreet.ca | ||
| 08.06. | Aclarion, Inc.: Aclarion Rejects Echo Lake Capital's Unsolicited Acquisition Proposal | 1.272 | GlobeNewswire (Europe) | BROOMFIELD, Colo., June 08, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc. ("Aclarion" or the "Company") (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers... ► Artikel lesen | |
| 08.06. | Aclarion, Inc.: Aclarion Stockholders Approve All Proposals at 2026 Annual Meeting | 174 | GlobeNewswire (Europe) | BROOMFIELD, Colo., June 08, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers... ► Artikel lesen | |
| ACLARION Aktie jetzt für 0€ handeln | |||||
| 04.06. | Aclarion, Inc. - 8-K, Current Report | 4 | SEC Filings | ||
| 03.06. | Aclarion, Inc.: Aclarion Adds Institute of Neuro Innovation to Support Nociscan Growth and Real-World Evidence Generation | 2 | GlobeNewswire (USA) | ||
| 01.06. | Aclarion's Nociscan technology used in back pain study | 2 | Investing.com | ||
| 01.06. | Aclarion, Inc.: Aclarion Technology Demonstrates Potential Beyond Surgical Planning in New Immune-Biomarker Study | 2 | GlobeNewswire (USA) | ||
| 28.05. | Aclarion, Inc. Comments on Echo Lake Capital's Letter and Unsolicited Proposal | 88 | GlobeNewswire (Europe) | BROOMFIELD, Colo., May 28, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary... ► Artikel lesen | |
| 28.05. | Echo Lake Capital Offers To Acquire Aclarion Inc. | 271 | ACCESS Newswire | Offers $4.00 per share in cash plus CVRStock currently trades below the value of its cash and other assetsBelieves company's public shell worth at least another $6 million if Board effected a reverse... ► Artikel lesen | |
| 13.05. | Aclarion, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 07.05. | Aclarion erweitert CLARITY-Studie um renommierte Privatpraxis für Wirbelsäulenchirurgie | 1 | Investing.com Deutsch | ||
| 07.05. | Aclarion adds Lanman Spinal Neurosurgery to CLARITY trial | 1 | Investing.com | ||
| 07.05. | Aclarion, Inc.: Aclarion Announces Addition of First Private Practice Site in Los Angeles into CLARITY Trial to Further Accelerate Enrollment | 1 | GlobeNewswire (USA) | ||
| 06.05. | Aclarion, Inc.: Aclarion Announces Inducement Grant to New Commercial Director, Western U.S. | 1 | GlobeNewswire (USA) | ||
| 05.05. | Aclarion establishes second trial agreement with Weill Cornell | - | Investing.com | ||
| 05.05. | Aclarion schließt zweite Studienvereinbarung mit Weill Cornell ab | 5 | Investing.com Deutsch | ||
| 05.05. | Aclarion, Inc.: Aclarion Announces Second Commercial Agreement with Weill Cornell Medicine | 1 | GlobeNewswire (USA) |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| UNITEDHEALTH | 358,00 | +0,56 % | United Health Group - UNH: Der Krankenversicherer ist auf dem Weg der Besserung! | 20er-EMA bietet Support! Bessere Zahlen, höhere Gewinnprognose und sinkende Kosten: UnitedHealth (UNH) sendet nach einer schwierigen Phase wieder positive Signale an die Anleger! United Health Group... ► Artikel lesen | |
| INTUITIVE SURGICAL | 354,25 | +0,44 % | Opening Bell: Microsoft, Chevron, GE Vernova, Caterpillar, SpaceX, Apple, Bloom, Intuitive Surgical | Die US-Börsen sind am Donnerstag mit einer Erholungsbewegung in das verlängerte Wochenende gegangen. Der Dow Jones ' schloss mit einem moderaten Plus von 0,14 Prozent. Deutlich freundlicher präsentierte... ► Artikel lesen | |
| THERMO FISHER | 409,90 | +0,89 % | If You Invested $100 In Thermo Fisher Scientific Stock 15 Years Ago, You Would Have This Much Today | ||
| TELADOC HEALTH | 6,746 | +2,03 % | Teladoc Health extends rally to seventh straight session | ||
| BAXTER | 17,660 | +2,58 % | MediThinQ partners with Baxter unit to distribute 3D platform | ||
| INMODE | 11,670 | +0,69 % | InMode Ltd. - 6-K, Report of foreign issuer | ||
| ATOSSA THERAPEUTICS | 1,580 | -1,86 % | Atossa Therapeutics Inc: Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds | $4.5 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon exercise in full of warrants
SEATTLE, June 12, 2026 /PRNewswire/... ► Artikel lesen | |
| DENTSPLY SIRONA | 8,874 | -0,07 % | DENTSPLY SIRONA Inc.: Dentsply Sirona Appoints John Fortson as Chief Financial Officer | CHARLOTTE, N.C., June 11, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (Nasdaq: XRAY), the world's largest diversified manufacturer of professional dental products... ► Artikel lesen | |
| EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc. - 8-K, Current Report | ||
| PETMED EXPRESS | 1,496 | -5,08 % | What makes PetMed Express, Inc. (PETS) one of the Best Pet Care Stocks to Buy for Consistent Recurring Revenue? | ||
| CENTENE | 55,16 | -1,15 % | RBC Capital initiates Centene stock coverage at Sector Perform | ||
| TANDEM DIABETES | 12,500 | -0,79 % | Deutsche Bank initiates Tandem Diabetes stock with hold rating | ||
| ORGANON | 11,790 | +0,55 % | Organon and Henlius launch Prolia and Xgeva biosimilars in Canada | ||
| FRESENIUS | 39,900 | +0,91 % | DEUTSCHE BANK RESEARCH stuft Fresenius SE auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Fresenius auf "Buy" mit einem Kursziel von 55 Euro belassen. Die Bedenken im Deutschen Bundesrat bezüglich staatlicher Kürzungen... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 41,550 | +0,73 % | AKTIE IM FOKUS: FMC schwächeln nach Abstufung - 200-Tage-Linie im Blick | FRANKFURT (dpa-AFX) - Die Aktien von FMC ringen nach einer Abstufung durch das Bankhaus Metzler am Freitag wieder um ihre zuletzt zurückeroberte einfache 200-Tage-Linie. Mit minus 2,6 Prozent fielen... ► Artikel lesen |